Nystrom T, Gonon AT, Sjoholm A, Pernow J
The science of slowed gastrointestinal motility GLP-1 receptor agonists act on the gutbrain axis and are known to slow gastric emptying and overall gastrointestinal transit , contributing to early satiety and appetite suppression. As intestinal transit slows, the colon has more time to absorb water from stool , leading to hard, dry stools that are difficult to pass . Constipation is a common, dose-related adverse effect listed in FDA prescribing information for both Wegovy (semaglutide) and Zepbound (tirzepatide) and is most frequently reported during dose escalation , with improvement over time., Step-by-Step MD Protocol for Relief 1
This important nutrient supports metabolism of lipids and healthy energy levels
Direct comparative effectiveness data between GLP-1 patches and established injectable formulations remains limited, as transdermal GLP-1 delivery systems are still largely in developmental or early clinical trial phases
Gastroparesis, on the other hand, is a more serious and possibly long-lasting issue
Can I travel with it